TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16981914

Group type: EXPERIMENTAL
Intervention: 400 ms initial drive train
Number of subjects: 50

Group type: COMPARATOR
Intervention: 600 ms initial drive train
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall induction rates
Number of subjects: 50
Study: 14556870

Group type: EXPERIMENTAL
Intervention: Propafenone SR 425 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propafenone SR 325 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propafenone SR 225 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 0
Study: 10758989

Group type: EXPERIMENTAL
Intervention: Compression ratio (CR) 6:1
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Compression ratio (CR) 10:1
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Compression ratio (CR) 16:1
Number of subjects: 21

Group type: COMPARATOR
Intervention: Uncompressed images
Number of subjects: 21
Study: 8836744

Group type: EXPERIMENTAL
Intervention: Home-based upper-arm exercise program (3 exercises, 5 times a week for 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (weekly contact to equalize attention)
Number of subjects: 20
Study: 1389953

Group type: EXPERIMENTAL
Intervention: Medifoxamine 300-1000 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Timolol 20 mg
Number of subjects: 0
Study: 4073076

Group type: EXPERIMENTAL
Intervention: Ticarcillin plus clavulanate potassium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 20
Study: 30711522

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (43.5 Gy in 15 fractions over 3 weeks)
Number of subjects: 820

Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy (50 Gy in 25 fractions over 5 weeks)
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Number of subjects: 820

Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy
Number of subjects: 820
Study: 29366432

Group type: EXPERIMENTAL
Intervention: MYLO program
Number of subjects: 213

Group type: COMPARATOR
Intervention: ELIZA program
Number of subjects: 213
Study: 27140403

Group type: EXPERIMENTAL
Intervention: Dedicated call centre (SOS-HAE) for management of HAE attacks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual practice for management of HAE attacks
Number of subjects: 200
Study: 24139860

Group type: EXPERIMENTAL
Intervention: 100% of habitual number of chews (HNC)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 150% of habitual number of chews (HNC)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 200% of habitual number of chews (HNC)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 150% and 200% of habitual number of chews (HNC)
Number of subjects: 18
Study: 23067317

Group type: EXPERIMENTAL
Intervention: Levofloxacin-containing 7-day triple therapy (Levo triple)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Standard sequential therapy (SST-10)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Levofloxacin-containing sequential therapy (Levo-ST-10)
Number of subjects: 345

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 345
Study: 19417588

Group type: EXPERIMENTAL
Intervention: HBOC-201 (Hemopure)
Number of subjects: 27

Group type: COMPARATOR
Intervention: PRBC
Number of subjects: 27
Study: 18630547

Group type: EXPERIMENTAL
Intervention: Acupuncture compound anesthesia (electroacupuncture combined with intramuscular injection of Pethidine)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Simple Pethidine (intramuscular injection)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Acupuncture compound anesthesia
Number of subjects: 316

Group type: COMPARATOR
Intervention: Simple Pethidine
Number of subjects: 316
Study: 16195767

Group type: EXPERIMENTAL
Intervention: Lipid Replacement Therapy plus antioxidants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11830625

Group type: EXPERIMENTAL
Intervention: PMCT with segmental hepatic artery embolization and temporary interruption of hepatic venous flow
Number of subjects: 31

Group type: COMPARATOR
Intervention: PMCT with segmental hepatic artery embolization only
Number of subjects: 31
Study: 10363733

Group type: EXPERIMENTAL
Intervention: Sparfloxacin (400-mg loading dose followed by 200 mg once daily)
Number of subjects: 603

Group type: COMPARATOR
Intervention: Ciprofloxacin (750 mg twice daily)
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 603

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 603
Study: 8545460

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1778879

Group type: EXPERIMENTAL
Intervention: 3 g ceftriaxone iv once daily for three days
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 4 g ceftriaxone iv once daily for three days
Number of subjects: 59

Group type: COMPARATOR
Intervention: Chloramphenicol 3 g daily in divided doses for two days followed by 2 g daily for 12 days
Number of subjects: 59
Study: 6980231

Group type: EXPERIMENTAL
Intervention: 1200 mg oxaprozin (600 mg twice daily)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 3900 mg aspirin (975 mg four times a day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 31296647

Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (diet, physical activity, behavior modification)
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: N-ethyl-perfluorooctane sulfonamido acetic acid
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Perfluorodimethylhexane sulfonic acid
Number of subjects: 957
Study: 29758380

Group type: EXPERIMENTAL
Intervention: Alcohol Brief Intervention (BI) delivered via computer or therapist
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Alcohol Brief Intervention (BI)
Number of subjects: 475
Study: 27109630

Group type: EXPERIMENTAL
Intervention: Chimpanzee Adenovirus 63 Modified Vaccinia Ankara ME-TRAP heterologous prime-boost immunization
Number of subjects: 138
Study: 24490712

Group type: EXPERIMENTAL
Intervention: Abstinence and work group (n = 16)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Work-only group (n = 15)
Number of subjects: 46

Group type: COMPARATOR
Intervention: No-voucher control group (n = 15)
Number of subjects: 46
Study: 23265228

Group type: EXPERIMENTAL
Intervention: 7-week group intervention
Number of subjects: 116

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Economic analysis of intervention
Number of subjects: 116
Study: 20537469

Group type: EXPERIMENTAL
Intervention: Normal compression pressure garment therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low compression pressure garment therapy
Number of subjects: 0
Study: 17998496

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD) shock
Number of subjects: 458

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 458
Study: 14693987

Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption (4 glasses of whisky, 40 g ethanol daily)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (tap water)
Number of subjects: 23
Study: 12401630

Group type: EXPERIMENTAL
Intervention: Sevoflurane (SEVO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isoflurane (ISO)
Number of subjects: 60
Study: 12563776

Group type: EXPERIMENTAL
Intervention: Artesunate 6 mg/kg once every 2 weeks for 4 times
Number of subjects: 780

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 780
Study: 8547549

Group type: EXPERIMENTAL
Intervention: High-dose fentanyl (55 micrograms/kg) anesthesia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-dose fentanyl (55 micrograms/kg) anesthesia + thoracic epidural analgesia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-dose fentanyl (15 micrograms/kg) anesthesia + thoracic epidural analgesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 30
Study: 2230578

Group type: EXPERIMENTAL
Intervention: HRCh (local ultra‐high frequency hyperthermia in combination with radiotherapy and chemotherapy)
Number of subjects: 54

Group type: COMPARATOR
Intervention: RCh (radiotherapy and chemotherapy)
Number of subjects: 54
Study: 773416

Group type: EXPERIMENTAL
Intervention: Prophylactic factor VIII therapy (infusions given once weekly to achieve a post-infusion plasma concentration of at least 0.25 I.U./ml)
Number of subjects: 9
Study: 31144661

Group type: COMPARATOR
Intervention: White light magnification alone
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: BLI-contrast magnification
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: BLI-bright magnification
Number of subjects: 249
Study: 28527129

Group type: EXPERIMENTAL
Intervention: Plerixafor (240 µg/kg/day) + G‐CSF (filgrastim, 400 µg/m2/day) for 4 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: G‐CSF alone (G group)
Number of subjects: 14
Study: 25125385

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) alone for 7 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) plus Hydroxychloroquine (HCQ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aspirin (ASA) alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aspirin (ASA) plus Clopidogrel (CLOP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) alone or in combination with ASA
Number of subjects: 20
Study: 23149295

Group type: EXPERIMENTAL
Intervention: In-center hemodialysis 6 times per week
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Home nocturnal hemodialysis 6 times per week
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (both trials)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (Daily Trial)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (Nocturnal Trial)
Number of subjects: 299
Study: 21562238

Group type: EXPERIMENTAL
Intervention: Zinc supplement (15 mg zinc as ZnSO4)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control (200 g/d of wheat bread fortified with iron and folic acid, no zinc)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Moderate zinc fortification (7.5 mg zinc as ZnO)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: High zinc fortification (15 mg zinc as ZnO)
Number of subjects: 132
Study: 19221190

Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D supplementation (1,000 mg of elemental calcium carbonate and 400 IU of vitamin D(3) daily)
Number of subjects: 36282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36282

Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D supplementation
Number of subjects: 36282
Study: 16996354

Group type: EXPERIMENTAL
Intervention: Pelican multibite forceps
Number of subjects: 6

Group type: COMPARATOR
Intervention: Radial Jaw 3 (RJ3) double-bite forceps
Number of subjects: 6
Study: 12643319

Group type: EXPERIMENTAL
Intervention: Venoruton (hydroxyethyl rutosides) 1 g twice daily for 3 days (2 days before the flight and the day of the flight)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 164
Study: 12060966

Group type: EXPERIMENTAL
Intervention: Hot water bath at 39.5 degrees C
Number of subjects: 12
Study: 10085710

Group type: EXPERIMENTAL
Intervention: Angiotensinogen gene m235t polymorphism, ACE gene I/D polymorphism, ACE gene Pst I RFLP polymorphism
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control group (130 healthy pregnant women)
Number of subjects: 246
Study: 7981011

Group type: EXPERIMENTAL
Intervention: Quinapril 2.5 mg p.o.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2659289

Group type: EXPERIMENTAL
Intervention: Aztreonam + Cefotaxime (AZ + CE)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Amikacin + Cefotaxime (AM + CE)
Number of subjects: 33
Study: 790893

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 21
Study: 31311465

Group type: EXPERIMENTAL
Intervention: IVT+EVT
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: IVT alone
Number of subjects: 240

Group type: COMPARATOR
Intervention: nonreperfusion care
Number of subjects: 240
Study: 30028098

Group type: EXPERIMENTAL
Intervention: Autologous endometrial cell coculture (AECC)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Traditional in vitro fertilization (IVF)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Both groups (AECC and control)
Number of subjects: 134
Study: 26056202

Group type: EXPERIMENTAL
Intervention: LIFT Wellness Program (multifactorial fall-prevention intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Administrative control group
Number of subjects: 0
Study: 24067395

Group type: EXPERIMENTAL
Intervention: Intravenous myo-inositol at 60 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous myo-inositol at 120 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21802038

Group type: EXPERIMENTAL
Intervention: Hold-relax proprioceptive neuromuscular facilitation stretching (HR-PNF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Static stretching (SS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (left leg, no intervention)
Number of subjects: 30
Study: 19515113

Group type: EXPERIMENTAL
Intervention: Prescription drugs and dietary supplements
Number of subjects: 3070

Group type: EXPERIMENTAL
Intervention: Prescription drugs
Number of subjects: 3070

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 3070

Group type: EXPERIMENTAL
Intervention: Estrogen preparations
Number of subjects: 3070

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs, thyroid drugs, and estrogens
Number of subjects: 3070

Group type: EXPERIMENTAL
Intervention: Drugs for diabetes mellitus
Number of subjects: 3070

Group type: EXPERIMENTAL
Intervention: Multivitamins, glucosamine and chondroitin, and echinacea
Number of subjects: 3070
Study: 17607956

Group type: EXPERIMENTAL
Intervention: Diet C (increased cereal consumption)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Diet V (increased vegetable consumption)
Number of subjects: 57
Study: 14982510

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 11275667

Group type: EXPERIMENTAL
Intervention: Conventional approach
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Modified-conventional approach
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Modified Atraumatic Restorative Treatment (ART)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: All treatment groups combined
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 152
Study: 9210004

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 40
Study: 29925421

Group type: EXPERIMENTAL
Intervention: S-amlodipine (2.5 mg) plus chlorthalidone (25 mg)
Number of subjects: 170

Group type: COMPARATOR
Intervention: S-amlodipine (2.5 mg) plus telmisartan (40 mg)
Number of subjects: 170
Study: 26791992

Group type: EXPERIMENTAL
Intervention: Computerized medication reviews conducted by expert teams
Number of subjects: 150
Study: 24771015

Group type: EXPERIMENTAL
Intervention: Zinc-fortified drinking skim milk (Zn-FMilk) for 2 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard non-fortified milk (No-FMilk)
Number of subjects: 0
Study: 22508964

Group type: EXPERIMENTAL
Intervention: Gelofusine (4% succinylated gelatine)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Voluven (6% hydroxyethyl starch)
Number of subjects: 25
Study: 20119816

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg, 3 times daily) with dietary treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Dietary treatment only
Number of subjects: 21
Study: 16460484

Group type: EXPERIMENTAL
Intervention: rabeprazole, amoxicillin, and minocycline
Number of subjects: 167

Group type: COMPARATOR
Intervention: rabeprazole, amoxicillin, and clarithromycin
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: rabeprazole, minocycline, and metronidazole
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: rabeprazole, minocycline, and faropenem
Number of subjects: 167
Study: 14722033

Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin (DC)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Vindesine plus cisplatin (VdsC)
Number of subjects: 311
Study: 11455735

Group type: EXPERIMENTAL
Intervention: Closed system (CS) suctioning
Number of subjects: 14

Group type: COMPARATOR
Intervention: Open system (OS) suctioning
Number of subjects: 14
Study: 9798793

Group type: EXPERIMENTAL
Intervention: NIDA/CA-developed standard intervention (SI)
Number of subjects: 3743

Group type: EXPERIMENTAL
Intervention: SI plus a site-specific enhanced intervention (EI)
Number of subjects: 3743
Study: 7803769

Group type: EXPERIMENTAL
Intervention: Somatostatin receptor scintigraphy with 111In-labeled octreotide
Number of subjects: 40
Study: 3378560

Group type: EXPERIMENTAL
Intervention: Combination therapy with levodopa and bromocriptine
Number of subjects: 702

Group type: COMPARATOR
Intervention: Levodopa therapy
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Bromocriptine monotherapy
Number of subjects: 702
Study: 5811680

Group type: EXPERIMENTAL
Intervention: Fluid therapy with 2 litres of Ringer‐lactate solution transfused in one hour during surgery.
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group receiving 2 litres of Ringer‐lactate solution transfused in one hour.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Patients under varying conditions of anaesthesia and surgery.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Surgery and anaesthesia conditions.
Number of subjects: 29
Study: 31785190

Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS) plus Multicomponent Therapy (MT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Multicomponent Therapy (MT) alone
Number of subjects: 39
Study: 31625118

Group type: EXPERIMENTAL
Intervention: Heart Rate ≤ 60 bpm
Number of subjects: 330

Group type: COMPARATOR
Intervention: Heart Rate 61-80 bpm
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Heart Rate > 80 bpm
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Beta-blocker use
Number of subjects: 330

Group type: COMPARATOR
Intervention: No beta-blocker use
Number of subjects: 330
Study: 27753739

Group type: EXPERIMENTAL
Intervention: Rutoside (600-1200 mg.d) and hydrolytic enzymes (540-1080 mg.d bromelain, 288-576 mg.d trypsin)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Rutoside and hydrolytic enzymes (WOB)
Number of subjects: 138
Study: 25282631

Group type: EXPERIMENTAL
Intervention: WBV plus exercise group
Number of subjects: 159

Group type: COMPARATOR
Intervention: Exercise group (stationary surface)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 159
Study: 23084490

Group type: EXPERIMENTAL
Intervention: Birth seat position
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Any other position (control)
Number of subjects: 1002
Study: 21526985

Group type: EXPERIMENTAL
Intervention: Usual care plus case management
Number of subjects: 102

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 102
Study: 18305926

Group type: EXPERIMENTAL
Intervention: MDMA (100 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ethanol (maintained at 0.6 per thousand)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Co-administration of MDMA and ethanol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17230421

Group type: EXPERIMENTAL
Intervention: Consecutive-day blood sampling
Number of subjects: 106

Group type: COMPARATOR
Intervention: Single-day blood sampling
Number of subjects: 106
Study: 15207663

Group type: EXPERIMENTAL
Intervention: Spontaneous placental delivery
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Manual placental delivery
Number of subjects: 400
Study: 11268296

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Markers of estrogen deficiency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individualized clinical approach to HRT
Number of subjects: 0
Study: 9429882

Group type: EXPERIMENTAL
Intervention: Application of a pneumatic tourniquet during open reduction and internal fixation of malleolar fractures
Number of subjects: 0

Group type: COMPARATOR
Intervention: No tourniquet use (control group)
Number of subjects: 0
Study: 7964515

Group type: EXPERIMENTAL
Intervention: CD8+ T cell clones from HIV-infected individuals
Number of subjects: 0

Group type: COMPARATOR
Intervention: CD8+ T cell clones from healthy individuals
Number of subjects: 0
Study: 3661647

Group type: EXPERIMENTAL
Intervention: Q-switched Nd:YAG laser treatment
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no laser treatment)
Number of subjects: 105
Study: 29985811

Group type: EXPERIMENTAL
Intervention: GlideScope video laryngoscope (GS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Direct laryngoscope (DL)
Number of subjects: 70
Study: 28462880

Group type: EXPERIMENTAL
Intervention: Abangane support group intervention
Number of subjects: 453

Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 453
Study: 25493952

Group type: EXPERIMENTAL
Intervention: Strict blood pressure control (mean arterial pressure under 92 mm Hg)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Usual blood pressure control (mean arterial pressure under 107 mm Hg)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Strict blood pressure control
Number of subjects: 840

Group type: COMPARATOR
Intervention: Usual blood pressure control
Number of subjects: 840